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Combination of anti-vascular  
agent - DMXAA and HIF-1α 
inhibitor - digoxin inhibits the 
growth of melanoma tumors
Ryszard Smolarczyk1, Tomasz Cichoń1, Ewelina Pilny1,2, Magdalena Jarosz-Biej1,  
Aleksandra Poczkaj1, Natalia Kułach1,3 & Stanisław Szala1
Vascular disrupting agents as DMXAA inhibit tumor growth only for a short period of time followed 
by rapid tumor regrowth. Among others, hypoxia and presence of transcription factor HIF-1α are 
responsible for tumors regrowth. The aim of our study was to investigate the inhibition of murine 
melanoma growth by combining two agents: anti-vascular - DMXAA and the HIF-1α inhibitor - digoxin 
and explaining the mechanism of action of this combination. After DMXAA treatment tumor size 
was reduced only for a limited time. After 7 days regrowth of tumors was observed and number of 
vessels was increased especially in tumor’s peripheral areas. DMXAA also induced an influx of immune 
cells: macrophages, CD8+ cytotoxic lymphocytes, NK cells, CD4+ lymphocytes. Administration of 
digoxin alone inhibited the growth of tumors. Administration of both agents in the proper sequence 
significantly inhibited the regrowth of tumors better than either agents alone. Combination therapy 
reduced number of newly formed vessels. In tumors of mice treated with combination therapy, the 
number of macrophages M1, CD8+ cytotoxic lymphocytes, NK cells and to a lesser extent CD4+ 
cells was increased. The combination of anti-vascular agents with HIF-1α inhibitors appears to be an 
effective therapeutic option.
Targeting of tumor associated blood vessels is one of the goals of anti-cancer therapy. Currently, two therapeutic 
strategies are known: one of them is anti-angiogenic therapy, which inhibits the formation of new blood ves-
sels, the second one, anti-vascular therapy, destroys existing blood vessels in tumors. A significant limitation of 
anti-angiogenic therapy is drug resistance emergence. Anti-vascular drugs (Vascular Disruptive Agents – VDA) 
specifically destroy existing blood vessels in tumor and reduce the tumor volume1. Around the damaged blood 
vessels, extensive areas of hypoxia and necrosis appear. Enhanced infiltration of immune cells is also observed. The 
most known anti-vascular drugs include DMXAA, combretastatin A-4 disodium phosphate (CA4P), Plinabulin 
(NPI-2358). CA4P and NPI-2358 are microtubule destabilizing drugs2,3. DMXAA (5,6-Dimethylxanthenone-
4-acetic Acid; also known as: ASA404, Vadimezan) is a xanthene which induces apoptosis in tumor vascular 
endothelium cells what results in necrosis appearance at tumor core. It activates the TANK-binding kinase 1/
interferon regulatory factor 3 (TBK1/IRF3) signaling pathway in leukocytes, inducing type-I-interferon (IFN-I) 
production4,5. DMXAA vascular disrupting properties are partly mediated by TNF-α signaling6. DMXAA acti-
vates the mitochondria- and endoplasmic reticulum-associated protein known as stimulator of interferon genes 
(STING)7,8.
Promising results of DMXAA obtained in preclinical studies on mice have not been confirmed in research 
involving humans. The reason for the lack of efficacy of this therapeutical approach is the specificity of only 
murine STING protein stimulation by DMXAA9,10. Currently the compounds interacting with a human STING 
protein such as synthetic cyclic dinucleotide (CDN) - cyclic guanosine monophosphate-adenosine monophos-
phate (cyclic GMP-AMP, or cGAMP) are known7,11,12. cGAMP activate STING pathway, through bounding to 
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STING protein, followed by phosporylation of TANK-binding kinase 1 (TBK-1) and Interferon Regulatory Factor 
3 (IRF-3) induce production of interferon-β13,14. Other compounds are derivatives of DMXAA15,16, that activate 
human STING protein as effectively as DMXAA does in mice.
However, the effect of anti-vascular drugs has its limitations. Destruction of neoplastic blood vessels is asso-
ciated with the appearance of inflammation, hypoxia and activation of HIF-1α protein in tumors, which in turn 
leads to formation of new blood vessels and tumor regrowth17–19. Digoxin is an inhibitor of HIF-1α protein 
translation and HIF-2α mRNA expression17,20. Digoxin reduces the amount of HIF-1α transcription factor, and 
consequently inhibits the growth of tumors in mice20. Recent data also indicate that digoxin inhibits endothelial 
focal adhesion kinase and angiogenesis21. The aim of our work was to combine the action of an anti-vascular 
drug - DMXAA with HIF-1α inhibitor - digoxin in the treatment of mice with B16-F10 melanoma tumors and to 
examine the mechanism of action of this combination.
Results
The combination of DMXAA and digoxin inhibits the growth of B16-F10 murine melanoma. 
Single, intraperitoneal administration of DMXAA at a dose of 25 mg/kg body weight inhibits tumor growth in 
treated mice compared to control mice that received a PBS− solution (Fig. 1). However, since 4th day after admin-
istration tumor regrowth was observed. Intraperitoneal administration of digoxin alone (7 times) at a dose of 
2 mg/kg body weight inhibits the growth of melanoma tumors in mice. Combination of DMXAA and digoxin 
inhibits tumor progression in treated mice more effectively than either of the compounds alone. At the 19th day 
of the experiment the volume of tumors in mice treated with DMXAA was about 65% smaller than the volume 
of control tumors. In digoxin-treated mice, the tumor volume was 54% smaller than control tumors. Whereas 
volume of tumors in mice treated with the combination therapy was 84% smaller than in control mice. Inhibition 
of tumor growth after administration of DMXAA and digoxin was statistically significant compared to each of 
the compounds alone (p < 0,005).
Administration of DMXAA and digoxin reduces the number of blood vessels in the tumor and 
increases the infiltration of immune cells. Damaged blood vessels in tumors and significant infiltration 
of immune cells were observed after two days after DMAA was administered to mice with tumors (vol. about 
40 mm) (Figs 2 and 3A,B). The area occupied by blood vessels within the tumor was reduced from 2.4% in the 
control tumors to 0.6% in the group that received DMXAA. However, after 6 days, regrowth of tumors in periph-
eral zone was observed, and area occupied by the blood vessels increased to 1.7%. Administration of digoxin 
alone (5 times) also reduced the area occupied by blood vessels on 6th day of the therapy from 2.4% in the group 
receiving PBS− up to 1.4% in treated group. Administration of both DMXAA and digoxin (after 6 days of therapy) 
significantly reduces the area occupied by blood vessels to 1%. In addition, significant infiltration of immune cells 
was observed around the damaged blood vessels, in group that received DMXAA alone and in group that received 
DMXAA and digoxin (Fig. 2).
HIF-1α identification in melanoma tumors. Administration of DMXAA to mice bearing B16-F10 
melanoma increases the amount of HIF-1α transcription factor in tumors comparing to the control mice that 
received the PBS− solution. Administration of digoxin to mice, both the group that received digoxin alone and 
the group that previously received DMXAA, reduced the amount of HIF-1α transcription factor in tumors – the 
intensity of the green fluorescence after antibody against HIF-1α staining was lower compared to the mice that 
received PBS− and DMXAA (Fig. 4A,B).
The effect of DMXAA and digoxin on M1 macrophages infiltration in tumors. Administration of 
both DMXAA alone and the combination of DMXAA and digoxin caused cytotoxic M1 macrophages (F4/80+/
CD206−) infiltration. The administration of digoxin alone does not change the number of M2 (F4/80+/CD206+) 
Figure 1. Treatment of mice bearing B16-F10 tumors with DMXAA and digoxin. DMXAA was administered 
once (25 mg/kg) and digoxin 7 times (2 mg/kg). Inhibition of tumor growth was statistically significant 
(*p < 0,05) after administration of combined therapy.
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and M1 (F4/80+/CD206−) macrophages. In mice treated with DMXAA alone as well as with DMXAA and 
digoxin combination, M1 macrophages infiltration was observed in areas where tumor cells were present, fol-
lowed by migration of M2 macrophages repairing the lesion site (Fig. 5).
Identification of CD4+, CD8+ and NK immune cells in melanoma tumors. Administration of both 
DMXAA alone and a combination of DMXAA and digoxin to mice bearing melanoma significantly increased 
the percentages of CD8+ and NK cells. Percentage of CD8+ cells increased from 1.4% in the group that received 
PBS− solution to 26.1% in the group receiving DMXAA and to 32.3% in the group that received the combination 
of DMXAA and digoxin. The level of CD4+ cells was also changed from 2.4% - (PBS−) to 8.7% (DMXAA) and 
7.5% (DMXAA + digoxin). Percentages of both CD8+, CD4+ and NK cells did not significantly change in the 
group that received digoxin alone in relation to the group receiving PBS− (Fig. 6A,B).
Figure 2. Hematoxylin and eosin staining after administration of DMXAA and digoxin. After administration 
of DMXAA and combined therapy destroyed blood vessels and infiltration of immune cells in the tumors were 
observed. Digoxin was shown to reduce the area of necrosis in tumors. Lens magnification 10×.
www.nature.com/scientificreports/
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Figure 3. The area occupied by blood vessels in tumors after treatment with DMXAA and digoxin. DMXAA 
significantly decreases the area of blood vessels in the tumor (*p < 0,05). After digoxin administration it is only 
slightly reduced. 7 days after DMXAA administration the vessels area increases while in the group treated with 
the combined therapy it is significantly smaller.
Figure 4. HIF-1α identification in tumors. The amount of HIF-1α factor decreased in tumors of mice that 
received digoxin and combined therapy compared to mice that received PBS and DMXAA (p < 0.05). In the 
group of mice that received DMXAA, the amount of HIF-1α increased (no statistical significance).
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A proposed scheme of action of DMXAA and digoxin. A single intraperitoneal administration of 
DMXAA causes destruction of existing blood vessels in tumor. Destruction of blood vessels causes the formation 
of hypoxia areas in which the level of the HIF-1α transcription factor increases. One of the effects of increased 
amount of HIF-1α is the formation of new blood vessels, which results in tumor regrowth. In addition, activation 
of HIF-1α activates a number of mechanisms that promote tumor growth, such as immunosuppression, genetic 
instability, activation of autophagy, increased invasiveness and cancer cell survival. Inhibition of HIF-1α activity 
after digoxin administration inhibits the regrowth of tumors (Fig. 7).
Discussion
Therapy that targets blood vessels effectively inhibits the growth of tumors. The anti-angiogenic therapy, which 
inhibits formation of new capillaries, has its limitations involving the possible resistance to anti-angiogenic drugs. 
Activation of alternative mechanisms of new blood vessels formation is stimulated. The use of anti-vascular drugs 
that destroy existing blood vessels in tumors seems to be effective therapeutical approach. These drugs specifically 
recognize and destroy blood vessels in tumors. There are some antivascular drugs that are used in early-phase 
of clinical trials. CKD-516 is a newly developed vascular disrupting agent. Study confirms the efficacy of this 
drug in patients with advanced solid tumors22. 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA, Vadimezan, 
ASA404) appears to be the most thoroughly tested drug in this group. The drug is effective in inhibiting the 
growth of murine glioma, acute myeloid leukaemia, B16.F10 melanoma, endocrine tumors, non-small cell lung 
cancer6–8,12,23. Our results confirm the effectiveness of inhibition of B16-F10 murine melanoma tumors growth 
after the administration of DMXAA in a dose of 25 mg/kg body weight.
However, clinical studies with DMXAA conducted on patients did not confirm the expected results. The rea-
son for the failure were differences in structure of murine and human stimulator of the interferon genes protein 
(STING)9,10. Nowadays the intensive research efforts are made for the human analogue of this drug. Downey’s 
et al. and Corrales’ et al. results indicate that synthetic cyclic dinucleotides activate STING protein in humans as 
DMXAA does in mice7,12. Synthetic cyclic dinucleotides (CDNs) are cyclic guanosine monophosphate-adenosine 
monophosphate (cyclic GMP-AMP, or cGAMP)7,11,12. cGAMP binds to STING, leading to the activation of IRF3 
and induction of interferon-I cytokines13,14. Other studies indicate that the modification of the DMXAA structure 
causes that the compound becomes ligand of human STING protein15,16. Thus, the analogues of the DMXAA 
Figure 5. Identification of macrophages in murine melanoma after administration of DMXAA and digoxin. 
Cytotoxic (M1) macrophages F4/80+/CD206− infiltration was observed after administration of DMXAA and 
digoxin. Digoxin alone does not alter the level of macrophages F4/80+/CD206+ (M2) and F4/80+/CD206− (M1).
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Figure 6. Presence of immune cells in murine melanoma after administration of DMXAA and digoxin. 
DMXAA alone and the combination of DMXAA with digoxin increase the levels of CD8+ lymphocytes, NK 
cells and to a lesser extent CD4+ lymphocytes (A). Digoxin alone does not change CD8+, CD4+, NK cells 
contribution comparing to control (PBS−). Representative plots of cytometric analysis (B).
Figure 7. Scheme of action of the drugs. DMXAA administration to mice bearing tumors leads to the 
destruction of existing tumor blood vessels. Destruction of the vessels results in the formation of hypoxia areas 
where HIF-1α transcription factor expression is increased. Activation of HIF-1α triggers several mechanisms 
that promote tumor growth. Inhibition of HIF-1α after digoxin administration supresses tumor regrowth.
www.nature.com/scientificreports/
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compound effectively stimulate the STING receptor (work in humans like DMXAA does in mice) which is no 
longer a species barrier.
The problem with the use of anti-vascular drugs is the stimulation of necrosis around the damaged blood 
vessels and an increase of hypoxia areas in tumor that leads to HIF-1α transcription factor activation. The 
factor is responsible for a number of processes in tumors. Among others, it stimulates the formation of new 
blood vessels, increases survival, proliferation potential and invasiveness of tumor cells and finally activates 
immunosuppression17–19,24.
In our study, 7 days after the administration of DMXAA, an upregulation of HIF-1α level and the number of 
blood vessels in the tumor were observed what in consequence led to tumor regrowth. Tumors regrowth periph-
erally with central area occupied by extensive necrosis and with increased number of blood vessels in marginal 
zone. Therefore, it seems that downregulation of the HIF-1α transcription factor may bring an additional thera-
peutic effect in approach using anti-vascular drugs. Many inhibitors of Hypoxia Inducible Factor 1 are currently 
known25. One of them is a drug used in treatment of cardiovascular system diseases - digoxin. The work of Zhang 
H and co-workers has shown that digoxin reduces the expression of HIF-1α in cells20. Other work showed that 
the density of blood vessels in prostate cancer was inhibited after digoxin treatment26. Our studies confirm these 
observations and show that the use of digoxin in the treatment of murine B16-F10 melanoma at a dose of 2 mg/
kg body weight: reduces level of HIF-1α in tumors of treated mice (the factor is not inhibited but its quantity is 
significantly reduced), inhibits the growth of tumors, and also, in combination with anti-vascular agent DMXAA, 
restrains tumor regrowth (compared with mice that received only DMXAA). We observed a reduction of blood 
vessels area after digoxin treatment but it wasn’t statistically significant. It seems that the use of an agent strongly 
inhibiting HIF-1α could bring even better therapeutic effect.
DMXAA, besides the destruction of existing vessels, stimulates the immune response in mice. The stimulation 
is carried out by reprogramming proangiogenic and immunosuppressive M2 macrophages towards cytotoxic M1 
phenotype12,27. Hypoxia, emerged in tumors, causes suppression of T lymphocytes, inhibits maturation of den-
dritic cells and activation of NK cells. Treg cells, tumor-associated macrophages and neutrophils are activated28. 
Our studies have shown that DMXAA increases the levels of M1 macrophages in tumors of both groups – the one 
that received DMXAA alone and in the group that received DMXAA and digoxin combination. We also observed 
that cytotoxic M1 macrophages that destroyed neoplastic cells were followed by M2 macrophages repairing 
damaged tumor sites. Besides the stimulation of macrophages to destroy cancer cells, we observed a significant 
increase in the percentages of CD8+ cytotoxic lymphocytes and NK cells and to a lesser extent increased percent-
age of CD4+ cells in the groups that received both DMXAA alone and the combination of DMXAA and digoxin. 
Digoxin alone did not induce significant changes in the number of immune cells compared to the control group.
The improvement in the therapeutic efficacy of DMXAA in combination with digoxin is therefore both the 
effect of inhibiting the HIF-1α protein and stimulating the immune system that activates macrophages, CD8+ 
cytotoxic lymphocytes, NK cells and CD4+ lymphocytes to destroy cancer cells in the tumor29.
The increase in the number of blood vessels is associated with a rapid regrowth of the tumor. In combined 
therapy, the number of vessels does not increase as with monotherapy with DMXAA. Using a combination of 
both therapeutic agents the growth of tumors may be controlled.
The use of anti-vascular drugs as DMXAA in combination with HIF-1α transcription factor inhibitors may 
supress tumor regrowth.
Methods
Mice and cell line. Mice (6- to 8-week-old, C57Bl/6NCrl females) were obtained from Charles River 
Breeding Laboratories. Mice were housed in a pathogen-free facility in SPF standard. Animals were treated in 
accordance with the European Community guidelines. The protocol was approved by the Committee on the 
Ethics of Animal Experiments of the Local Ethics Commission (Medical University of Silesia, Katowice, Poland). 
Murine melanoma B16-F10 (ATCC) were propagated in RPMI 1640 supplemented with 10% fetal bovine serum. 
Cell cultures were maintained in a standard 37 °C/5% CO2 incubator. Cells were passaged every 3–4 days.
Agents used in the experiments. DMXAA was purchased from Slleckchem (Houston, TX, USA), catalog 
number: S1537. Digoxin was purchased from Sigma-Aldrich (St Louis, MO, USA), catalog number: D6003.
Therapy of mice bearing B16-F10 melanoma tumors. Seven days after inoculating mice (lower flank) 
with B16-F10 melanoma cells (2 × 105 cells/100 µL PBS-), intraperitoneal injection of DMXAA-treated mice were 
initiated at dose 25 mg/kg body weight. Next day after DMXAA injection digoxin (2 mg/kg body weight) was 
administered intraperitoneally to appropriate groups of mice (digoxin and DMXAA + digoxin groups). Digoxin 
was administered daily for seven consecutive days. Tumor volume was monitored. Tumors were measured with 
calipers and tumor volumes were determined using the formula: volume = width 2 × length × 0.52.
Immunohistochemistry. In days 2 and 7 after DMXAA and digoxin administrations tumors were embed-
ded in liquid nitrogen and sectioned into 5μm slices. To determine the presence of the blood vessels in col-
lected tumors, frozen sections were stained using antibody directed against CD31 antigen (Abcam; Ab7388, 1:50, 
Cambridge, UK). Area occupied by blood vessels was counted with ImageJ software (NIH). Stained blood vessels 
were counted in 5 randomly chosen fields (magn. 20×) per section in 4 tumors of each group. To determine the 
presence of macrophages with M2 phenotype in collected tumors frozen sections were stained using antibody 
directed against CD206 antigen (Abcam; Ab64693, 1:100, Cambridge, UK). Additional identification of mac-
rophages were performed using an antibody against F4/80 antigen (Abcam; Ab6640, 1:100, Cambridge, UK). 
To determine the presence of hypoxia-inducible factor 1 in collected tumors, frozen sections were stained using 
antibody directed against HIF-1 antigen (Abcam; Ab179483, 1:100, Cambridge, UK). To identify the primary 
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antibodies the secondary antibodies conjugated with fluorochromes were used (FITC, Texas Red) (Vector 
Laboratories, FI-1200, 1:100; Burlingame, USA). Sections were mounted in VECTASHIELD Mounting Medium 
with DAPI (Vector Laboratories, H-1200). The fluorescence intensity was measured with ImageJ software (NIH). 
Microscopic observations were performed using an LSM 710 Zeiss confocal microscope (Carl Zeiss Microscopy 
GmGB, Gottingen, Niemcy).
Histochemical staining. In days 2 and 7 after DMXAA and digoxin administrations tumors were collected, 
fixed in PFA and paraffin-embedded. Paraffin sections were examined histochemically (hematoxylin/eosin 
staining). Analysis of histochemistry specimens were performed using Nikon Eclipse 80i microscope (Nikon 
Instruments Inc., Melville, NY, USA).
Determination of immune system cells after antitumor therapy. Mice were sacrificed on the 14th 
day of the experiment. Tumors were collected for flow cytometric analysis; single-cell suspension was obtained 
using a digestion mix (0.5 mg/mL collagenase A, Sigma Aldrich; 0.2 mg/mL hyaluronidase type V, Sigma Aldrich; 
0.02 mg/mL DNase I, Roche; per 0.25 g of tumor tissue). Red blood cells were lysed using 0.15 M ammonium 
chloride (Sigma Aldrich). Dead cells were removed by centrifugation using Lympholyte-M gradients (Cedarlane, 
Ontario, Canada). To identify the subpopulations of T lymphocytes, the following antibodies were used: 
PE-Cy7TM-CD3e, PE-CD4 and APC-CD8a (BD Pharmingen, catalog number: 558431, component: 51-9000790). 
The titers of antibodies was performed in accordance with the manufacturer’s instructions. Finally, to identify the 
level of NK cells, an anti-mouse CD49b (pan-NK cells) antibody was used (1 µg/106 cells; eBioscences, catalog 
number: 17-5971-82). In flow cytometric analyses (BD FACSCanto, BD), gate dividing negative from positive 
cells was based on isotype antibody control probes: PE-Cy™7 Hamster IgG1κ, PE and APC Rat IgG2aκ (BD 
Pharmingen, catalog number: 558431, component: 51-9000792) or APC Rat IgM (1 µg/106 cells, eBioscences, 
catalog number: 17-4341-82)30. The titers of antibodies was performed in accordance with the manufacturer’s 
instructions.
Statistics. For statistical analysis Kruskal-Wallis and multiple comparisons of mean ranks for all groups tests 
were used. Differences in p values of 0,05 or less were considered significant.
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